Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease

Next Previous
Trial Profile

The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trimetazidine (Primary)
  • Indications Angina pectoris; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms PATMOS

Most Recent Events

  • 01 Jun 2023 Status changed from recruiting to completed.
  • 07 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
  • 07 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top